Nicola Farina, Silvia Bellando-Randone, Sebastien Sanges, Hilde Jenssen Bjørkekjaer, Lorenzo Tofani, Marie-Elise Truchetet, Vanessa Smith, Andra Balanescu, Christina Bergmann, Yannick Allanore, Philipp Klemm, Simona Truglia, Luca Idolazzi, Christopher Denton, Roberta Foti, Anna Wojteczek, Emmanuel Chatelus, Madelon Vonk, Serena Guiducci, David Launay, Eric Hachulla, Jeska K de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, Oliver Distler, Marco Matucci-Cerinic, Cosimo Bruni
{"title":"Association between bosentan and reduced detection of precapillary pulmonary hypertension in systemic sclerosis: evidence from a EUSTAR study.","authors":"Nicola Farina, Silvia Bellando-Randone, Sebastien Sanges, Hilde Jenssen Bjørkekjaer, Lorenzo Tofani, Marie-Elise Truchetet, Vanessa Smith, Andra Balanescu, Christina Bergmann, Yannick Allanore, Philipp Klemm, Simona Truglia, Luca Idolazzi, Christopher Denton, Roberta Foti, Anna Wojteczek, Emmanuel Chatelus, Madelon Vonk, Serena Guiducci, David Launay, Eric Hachulla, Jeska K de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, Oliver Distler, Marco Matucci-Cerinic, Cosimo Bruni","doi":"10.1136/jsrd-2026-000044","DOIUrl":"10.1136/jsrd-2026-000044","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate whether exposure to vasoactive-vasodilating drugs (VVDs), particularly bosentan, is associated with reduced detection of precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc).</p><p><strong>Design: </strong>Post hoc retrospective case-control study.</p><p><strong>Setting: </strong>European Scleroderma Trials and Research database.</p><p><strong>Participants: </strong>SSc patients who underwent their first right heart catheterisation (RHC); patients with postcapillary PH (pulmonary wedge pressure >15 mm Hg) were excluded.</p><p><strong>Interventions: </strong>Exposure to VVDs (endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors, prostanoids) was defined as 'ever' before or 'ongoing' at the time of RHC.</p><p><strong>Main outcome measures: </strong>Presence of precapillary PH at RHC.</p><p><strong>Results: </strong>Among the 944 patients included in the study, 498 (53%) were diagnosed with precapillary PH. Bosentan 'ever' was associated with a lower likelihood of a precapillary PH detection (OR 0.594, 95% CI 0.362 to 0.975) in the whole population. When considering 'ongoing' bosentan exposure, this result was confirmed only in patients with current DU (OR 0.230, 95% CI 0.081 to 0.652). ERAs in general showed a trend for protective effects towards detection of precapillary PH in patients with current DU ('ever': OR 0.636, 95% CI 0.349 to 1.158; 'ongoing': OR 0.435, 95% CI 0.193 to 1.064), while other VVD classes did not.</p><p><strong>Conclusions: </strong>Bosentan, especially when employed in patients with current DU at the time of RHC, was associated with less detection of precapillary PH. These findings highlight the need for individualised treatment strategies and further research to optimise the timing and patient selection for VVD therapy in SSc.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 2","pages":"e000044"},"PeriodicalIF":1.5,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna-Maria Hoffmann-Vold, Oliver Distler, Yannick Allanore, Francesco Del Galdo, Christopher P Denton, Masataka Kuwana, Dinesh Khanna, Zsuzsanna H McMahan, Elizabeth R Volkmann, Hao Li, Mihaela Dumistracel, Martina Gahlemann, Susanne Stowasser, Shervin Assassi
{"title":"VERANDA-SSc: study design of a phase III, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in systemic sclerosis.","authors":"Anna-Maria Hoffmann-Vold, Oliver Distler, Yannick Allanore, Francesco Del Galdo, Christopher P Denton, Masataka Kuwana, Dinesh Khanna, Zsuzsanna H McMahan, Elizabeth R Volkmann, Hao Li, Mihaela Dumistracel, Martina Gahlemann, Susanne Stowasser, Shervin Assassi","doi":"10.1136/jsrd-2026-000052","DOIUrl":"10.1136/jsrd-2026-000052","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is a rare, heterogeneous, autoimmune disease. It involves a complex interplay of immune dysregulation, vasculopathy and fibrosis. There are no widely approved drugs that target all three underlying mechanisms and modify the overall SSc disease course or prevent overall disease progression. Nerandomilast, a preferential phosphodiesterase 4B inhibitor, has demonstrated antifibrotic, immunomodulatory and vasculoprotective effects in models relevant to SSc. The phase III VERANDA-SSc trial (NCT07497087) will investigate the efficacy and safety of nerandomilast in patients with SSc.</p><p><strong>Methods and analysis: </strong>This double-blind, randomised, placebo-controlled trial will be conducted at ~235 sites across 45 countries. Approximately 450 patients with SSc will be randomised 1:1 to receive 18 mg nerandomilast two times a day or placebo in addition to standard-of-care therapy. The dose may be reduced to 9 mg two times a day or interrupted based on individual tolerability or if used concomitantly with strong CYP3A inhibitors. Treatment will continue for at least 52 weeks and until the planned number of primary endpoint events is reached.Adult patients must meet the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria, have disease onset within 7 years and have active disease (key inclusion criteria permit the enrolment of patients with diffuse cutaneous or limited cutaneous SSc). Stable background immunosuppressive or nintedanib therapy is allowed.The primary endpoint is a composite of time to the first occurrence of predefined SSc-related clinically meaningful disease progression or complications, or confirmed absolute decline in forced vital capacity % predicted ≥5% (for patients with interstitial lung disease at baseline), or relative increase in modified Rodnan skin score (mRSS) ≥25% together with an absolute increase in mRSS ≥5 points, or all-cause death. Safety, pharmacokinetics, organ manifestations and patient-reported outcomes will also be assessed.</p><p><strong>Trial registration number: </strong>NCT07497087.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 2","pages":"e000052"},"PeriodicalIF":1.5,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pathogenesis of SSc-ILD.","authors":"Kristina Elizabeth Neergaard Clark","doi":"10.1136/jsrd-2026-000036","DOIUrl":"https://doi.org/10.1136/jsrd-2026-000036","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is the most common internal organ manifestation of systemic sclerosis (SSc) and remains the leading cause of disease-related mortality. The disease course is variable among patients, for although ILD develops in the majority of patients, only a subset progress to severe fibrotic lung disease, reflecting considerable biological heterogeneity. SSc-ILD evolves through distinct pathogenic phases, with early immune-mediated epithelial and endothelial injury giving way to autonomous fibroblast activation, extracellular matrix remodelling and self-sustaining fibrotic pathways. Insights from genetic and epigenetic studies, single-cell technologies, experimental models and, more recently, biosamples collected during clinical trials have substantially advanced our understanding of disease mechanisms and highlighted differences between early inflammatory and established fibrotic disease. This review aims to summarise the current understanding of the cellular and molecular mechanisms underlying SSc-ILD and discuss how these advances are shaping precision medicine approaches.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 2","pages":"e000036"},"PeriodicalIF":1.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A new dawn for autologous haematopoietic stem cell transplantation in systemic sclerosis in the era of cellular therapies.","authors":"Julia Spierings","doi":"10.1136/jsrd-2026-000040","DOIUrl":"https://doi.org/10.1136/jsrd-2026-000040","url":null,"abstract":"","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 2","pages":"e000040"},"PeriodicalIF":1.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dinesh Khanna, Mario Ehlers, Lizette Moros, Arpit Misra, Hyemin Song, Isabel Truman, Liane Gillespie-Akar, Francesco Del Galdo
{"title":"Novel clustering approach to understanding distinct phenotypes of patients with systemic sclerosis.","authors":"Dinesh Khanna, Mario Ehlers, Lizette Moros, Arpit Misra, Hyemin Song, Isabel Truman, Liane Gillespie-Akar, Francesco Del Galdo","doi":"10.1136/jsrd-2026-000041","DOIUrl":"https://doi.org/10.1136/jsrd-2026-000041","url":null,"abstract":"<p><strong>Objectives: </strong>Despite earlier clustering studies on systemic sclerosis (SSc), how clinical subgroups differ in disease burden, treatment and patient-physician dynamics remains unclear. This study applied a novel clustering method to identify clinical subgroups.</p><p><strong>Design: </strong>Data were analysed from 1906 adults with SSc and their treating rheumatologists across the USA, France, Germany, Italy, Spain, UK and Japan (March-September 2022).</p><p><strong>Setting: </strong>Data were collected by Adelphi Real World as part of an independent survey titled the SSc I Disease Specific Programme, comprising data from the USA, France, Germany, Italy, Spain, UK and Japan.</p><p><strong>Participants: </strong>Physicians completed case record forms; patients completed self-reported questionnaires. Latent class clustering was conducted using five physician-reported variables: affected body areas, symptoms, severity, flares in the past 12 months and remission status.</p><p><strong>Interventions: </strong>This was a non-interventional, observational, retrospective study.</p><p><strong>Main outcome measures: </strong>A cluster solution was selected based on model fit and clinical interpretability. We compared time to diagnosis, symptoms at diagnosis, postdiagnosis trajectories, physician management and patient treatment perspectives across clusters.</p><p><strong>Results: </strong>We identified four clusters representing a gradient of disease severity, with all clusters comprising >75% females. Clusters 1/2 comprised younger patients with fewer concomitant conditions; Clusters 3/4 showed greater internal organ involvement and disease severity. Raynaud's phenomenon (RP) was the most frequent first symptom (physician-reported: 73%-85%; patient-reported: 63%-79%), but those with first symptoms other than RP were diagnosed faster (mean 1.06 vs 1.62 years). Musculoskeletal involvement was most pronounced in Clusters 2/4. Postdiagnosis (3.7-7.2 years), the number of symptoms and affected body areas decreased in Cluster 1, increased in Cluster 4 and remained relatively stable in Clusters 2/3. Improvement in disease progression within the first 2 years postdiagnosis was more often reported in Clusters 1/2 vs 3/4 (33%-34% vs 8%-20%). Most patients across clusters reported that the main benefit they wanted from treatment was to get rid of the disease.</p><p><strong>Conclusions: </strong>This analysis improves understanding of SSc beyond limited/diffuse subtypes. Musculoskeletal involvement emerged as a contributor to SSc burden, supporting its integration into monitoring/stratification strategies for earlier identification of high-risk patients.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 2","pages":"e000041"},"PeriodicalIF":1.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13711579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marissa B Savoie, Jessica L Logeman, Flavia V Castelino
{"title":"Palliative care in systemic sclerosis: incorporating advance care planning into longitudinal care.","authors":"Marissa B Savoie, Jessica L Logeman, Flavia V Castelino","doi":"10.1136/jsrd-2026-000020","DOIUrl":"10.1136/jsrd-2026-000020","url":null,"abstract":"<p><p>Despite advances in rheumatological treatments, patients with systemic sclerosis (SSc) suffer with myriad symptoms and experience associated quality of life decrements. Although SSc-related mortality is reported around 53%, there is a paucity of existing literature describing advance care planning and palliative care in SSc. Here we review symptom management burden and strategies by organ manifestation: interstitial lung disease, pulmonary hypertension, gastrointestinal involvement, cutaneous and musculoskeletal manifestations and digital ischaemia. Then we review domains of palliative care in the context of SSc including psychosocial support, sharing prognostic information, discussing goals of care, advance care planning and comfort-focused care. Finally we suggest unmet research needs in palliative care and SSc.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 1","pages":"e000020"},"PeriodicalIF":1.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reshma Seomore, Matthew Wells, Ula Tymoszuk, Mithi Ahmed-Richards, Christopher P Denton, Francesco Del Galdo, Sue Farrington, Ariane L Herrick, Michael Hughes, Nick Jeffries-Owen, John D Pauling
{"title":"Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.","authors":"Reshma Seomore, Matthew Wells, Ula Tymoszuk, Mithi Ahmed-Richards, Christopher P Denton, Francesco Del Galdo, Sue Farrington, Ariane L Herrick, Michael Hughes, Nick Jeffries-Owen, John D Pauling","doi":"10.1136/jsrd-2026-000008","DOIUrl":"10.1136/jsrd-2026-000008","url":null,"abstract":"<p><strong>Objectives: </strong>Associations between Raynaud's phenomenon (RP) and body mass index (BMI), fibromyalgia syndrome (FMS) and migraine have been reported but their influence on the lived experience of RP is unknown.</p><p><strong>Design: </strong>Cross-sectional electronic survey.</p><p><strong>Setting: </strong>A social media-based awareness campaign organised by Scleroderma & Raynaud's UK.</p><p><strong>Participants: </strong>4141 respondents with RP, including 3279 with primary RP (PRP), 476 with systemic sclerosis-related RP (SSc-RP) and 386 with other systemic autoimmune rheumatic disease-related RP (SARD-RP).</p><p><strong>Interventions: </strong>Not applicable.</p><p><strong>Main outcome measures: </strong>RP symptom characteristics (colour change patterns, pain, numbness, tingling and thumb involvement) and their associations with BMI, FMS and migraine.</p><p><strong>Results: </strong>In PRP, low BMI correlated with higher prevalence of cyanosis (55.1% vs 41.2%), hyperaemia (48.2% vs 41.3%), triphasic change (30.4% vs 23.0%) and thumb involvement (36.0% vs 27.0%) compared with high BMI. In PRP, concomitant FMS was associated with higher prevalence of pain (77.7% vs 57.4%), cyanosis (53.8% vs 45.4%), tingling (72.6% vs 62.8%) and thumb involvement (46.2% vs 27.2%) compared with those without FMS. Higher prevalence of pain was reported by FMS respondents with SSc-RP (82.8% vs 69.9%) and SARD-RP (84.1% and 70.9%, respectively). In PRP, migraine was associated with higher prevalence of cyanosis (50.0% vs 44.9%), hyperaemia (50.3% vs 43.7%), pain (69.0% vs 56.2%) and thumb involvement (33.4% vs 27.1%). Migraine was associated with higher prevalence of hyperaemia and pain in SARD-RP.</p><p><strong>Conclusion: </strong>BMI, FMS and migraine influence the lived experience of RP, particularly in PRP. FMS is associated with a greater pain burden, whereas low BMI and migraine are associated with prominent vasospastic features. These aetiopathogenic drivers influence RP symptomatology, with implications for management.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 1","pages":"e000008"},"PeriodicalIF":1.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisavet Efthymiou, Eleni C Pardali, Arriana Gkouvi, Alexandros Mitropoulos, Christina G Katsiari, Eirini Koidou, Dimitrios G Goulis, Markos Klonizakis, Dimitrios P Bogdanos, Maria G Grammatikopoulou
{"title":"Knowledge and perceptions of medical practitioners on the role of nutrition in systemic sclerosis.","authors":"Elisavet Efthymiou, Eleni C Pardali, Arriana Gkouvi, Alexandros Mitropoulos, Christina G Katsiari, Eirini Koidou, Dimitrios G Goulis, Markos Klonizakis, Dimitrios P Bogdanos, Maria G Grammatikopoulou","doi":"10.1136/jsrd-2026-000005","DOIUrl":"10.1136/jsrd-2026-000005","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic sclerosis (SSc) presents complex manifestations that impact disease progression and quality of life. Despite the burden of gastrointestinal (GI) and nutrition-related symptoms, a lack of consensus is apparent regarding the appropriate dietary strategies to support SSc management. The present study aimed to explore the perspectives of rheumatologists regarding the importance of nutrition counselling and nutrition-related patients' needs.</p><p><strong>Methods: </strong>A cross-sectional study was conducted using a sample of 74 rheumatologists in Greece. The Views on Education and Nutrition in Scleroderma (VENUS) questionnaire was employed. The tool assesses three domains: demographics, scleroderma management and nutrition education approaches. Descriptive statistics summarised the findings, while comparisons and correlations were performed, where appropriate.</p><p><strong>Results: </strong>Physicians noted that patients with SSc requested dietary advice for symptom control (58.1%), improving general nutrition knowledge (32.4%) and adhering to specialised diets (29.7%). While practitioners recognised the importance of nutrition in SSc care, they emphasised the value of structured support, including face-to-face consultations (51.4%) and the integration of dietitians into multidisciplinary care teams (40.5%). Patients frequently sought nutritional advice, especially regarding reflux management (74.3%), soft-food diet (47.0%) and less commonly other dietary regimens. Regarding symptomatology, most rheumatologists reported pain, digital ulcers and GI discomfort in over half of their patients. Most commonly reported GI symptoms included reflux (89.2%), bloating (55.4%), heartburn (54.1%) and dysphagia (52.7%).</p><p><strong>Conclusion: </strong>Patients with SSc experience significant pain and GI disturbances and actively seek dietary guidance. Rheumatologists acknowledge the importance of nutrition in disease management and highlight the need for comprehensive multidisciplinary care models involving dietitians, aiming to improve patient outcomes.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 1","pages":"e000005"},"PeriodicalIF":1.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonia Valenzuela, Lorinda Chung, John D Pauling, Robyn Domsic, Lesley Saketkoo, Kim Fligelstone, Anne-Marie Russell, Dinesh Khanna, Tracy Frech, Laura Ross, Mandana Nikpour, Christopher Denton, Murray Baron
{"title":"Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis.","authors":"Antonia Valenzuela, Lorinda Chung, John D Pauling, Robyn Domsic, Lesley Saketkoo, Kim Fligelstone, Anne-Marie Russell, Dinesh Khanna, Tracy Frech, Laura Ross, Mandana Nikpour, Christopher Denton, Murray Baron","doi":"10.1136/jsrd-2026-000009","DOIUrl":"10.1136/jsrd-2026-000009","url":null,"abstract":"<p><p>The Scleroderma Clinical Trials Consortium (SCTC) is committed to advancing the understanding and treatment of systemic sclerosis (SSc). This review focuses on the development and validation of various outcome instruments by the SCTC, which are crucial for evaluating the effectiveness of interventions in clinical trials and observational studies. Key instruments discussed include the Assessment of Systemic Sclerosis-Associated RAynaud's Phenomenon Questionnaire, the SCTC Radiologic Scoring System for calcinosis, the Mawdsley Questionnaire for calcinosis, the University of California Los Angeles SCTC Gastrointestinal Tract Instrument (GIT) 2.0, the SCTC Activity Index and the SCTC Damage Index. Additionally, the SCTC and World Scleroderma Foundation (WSF) Skin Scoring Certification is highlighted as an important resource for researchers. Each instrument's purpose, description and validation process are examined, underscoring their pivotal role in advancing SSc research and improving patient outcomes.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 1","pages":"e000009"},"PeriodicalIF":1.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Transcriptomic profiling of myocardial biopsies reveals metabolic suppression and autophagy activation in systemic sclerosis-associated primary heart involvement.","authors":"Yohei Isomura, Yoshio Nakano, Yoshiaki Kubota, Tsunenori Saito, Satsuki Noma, Kai Miyazaki, Yukako Shintani-Domoto, Kuniya Asai, Satoru Miyazaki, Hayashi Yamamoto, Masataka Kuwana","doi":"10.1136/jsrd-2026-000003","DOIUrl":"10.1136/jsrd-2026-000003","url":null,"abstract":"<p><strong>Objectives: </strong>To characterise the myocardial transcriptomic landscape of patients with systemic sclerosis (SSc) with primary heart involvement (pHI) and identify molecular pathways underlying its pathogenesis.</p><p><strong>Design: </strong>A single-centre study exploring the molecular pathogenesis of SSc-pHI through transcriptomic analysis of endomyocardial biopsy specimens.</p><p><strong>Setting: </strong>Basic research.</p><p><strong>Participant: </strong>This study enrolled seven patients with SSc-pHI and eight patients with dilated cardiomyopathy (DCM) who had undergone endomyocardial biopsy for clinical practice purposes.</p><p><strong>Interventions: </strong>No intervention.</p><p><strong>Main outcome measures: </strong>Not applicable.</p><p><strong>Methods: </strong>Endomyocardial biopsy specimens from patients with SSc-pHI and those with DCM underwent whole RNA sequencing. To enable indirect comparison with non-failing (NF) myocardium, public RNA sequencing data of NF and DCM samples were integrated using DCM as a shared reference. Differential gene expression, pathway enrichment (Ingenuity Pathway Analysis and Gene Set Enrichment Analysis) and immune and stromal cell deconvolution were performed. Histopathological evaluation included LC3 immunostaining and transmission electron microscopy (TEM).</p><p><strong>Results: </strong>A total of 700 genes were differentially expressed between SSc and DCM myocardium. Mitochondrial energy metabolism pathways, including oxidative phosphorylation, fatty acid β-oxidation and the tricarboxylic acid cycle, were markedly suppressed in SSc. Indirect comparison with NF myocardium confirmed reciprocal regulation of mitochondrial metabolism and suggested enhanced autophagy. Cell deconvolution revealed enrichment of M1-like macrophages in SSc myocardium. LC3 immunostaining and TEM revealed increased autophagic vacuoles, lipid droplet accumulation and ischaemia-like ultrastructural alterations.</p><p><strong>Conclusions: </strong>SSc myocardium exhibits metabolic reprogramming characterised by mitochondrial dysfunction and enhanced autophagy, accompanied by macrophage activation.</p>","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":"11 1","pages":"e000003"},"PeriodicalIF":1.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}